Muscarinic Toxin 3

Leu-Thr-Cys-Val-Thr-Lys-Asn-Thr-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Ala-Gly-Gln-Asn-Leu-Cys-Phe-Lys-Arg-Trp-His-Tyr-Val-Ile-Pro-Arg-Tyr-Thr-Glu-Ile-Thr-Arg-Gly-Cys-Ala-Ala-Thr-Cys-Pro-Ile-Pro-Glu-Asn-Tyr-Asp-Ser-Ile-His-Cys-Cys-Lys-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys³-Cys²⁴, Cys¹⁷-Cys⁴², Cys⁴⁶-Cys⁵⁷, and Cys⁵⁸-Cys⁶³)
: (M.W. 7379.4) C₃₁₉H₄₈₉N₈₉O₉₇S₈
: Specific Ligand for Muscarinic Acetylcholine Receptor-4 (M4)

Package	Price(Yen)	Availability	Quantity
Vial 0.1 mg	30,000	Ships within 1-3 business days
バルク見積もり

Solubility: H₂O (50 μM)

K.N. Bradley, Pharmacol. Ther., 85, 87 (2000). (Review)
T.G. Beach, D.G. Walker, P.E. Potter, L.I. Sue, and A. Fisher, Brain Res., 905, 220 (2001). (Pharmacol.)
C. Hock, A. Maddalena, A. Raschig, F. Müller-Spahn, G. Eschweiler, K. Hager, I. Heuser, H. Hampel, T. Müller-Thomsen, W. Oertel M. Wienrich, A. Signorell, C. Gonzalez-Agosti, and R.M. Nitsch, J. Protein Folding Disord., 10, 1 (2003). (Pharmacol.)
Z. Gu, P. Zhong, and Z. Yan, J. Biol. Chem., 278, 17546 (2003). (Pharmacol; Inhibition of β -Amyloid signaling)
S. Katayama, M. Ishimaru, H. Nishio, Y. Nishiuchi, and T. Kimura, Peptide Science 2004, 161 (2005). (S-S Bond)
M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, and E. Karlsson, FEBS Lett., 352, 91 (1994). (Original; MT3)
J.-S. Liang, J. Carsi-Gabrenas, J.L. Krajewski, J.M. McCafferty, S.L. Purkerson, M.P. Santiago, W.L. Strauss, H.H. Valentine, and L.T. Potter, Toxicon, 34, 1257 (1996). (Original; m4-toxin)
A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.; Muscarinic Receptor Subtype Specificity)
M. C. Olianas, A. Adem, E. Karlsson, and P. Onali, Eur. J. Pharmacol., 357, 235 (1998). (Pharmacol.; cAMP-Coupled M4 Receptor)
M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, A. Oras, N. Satyapan, A. Adem, and E. Karlsson, Eur. J. Biochem., 234, 579 (1995). (Original)